Clinical trials: Women Contraception
Oral Contraception
A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest
Researchers want to learn more about user satisfaction in women in Russia who take estradiol valerate/ dienogest as a contraceptive in real conditions. Estradiol valerate/ dienogest is a form of birth control.
- Trial name
- Q-SWAN (NCT04901377)
- Testing
- Estradiol valerate/ Dienogest
- Where
- Russia
- Volunteers
- 255 people
- Sponsor
- Bayer
Obesity
A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant
This study medicine NNC0487-0111 to improve the treatment options for people living with overweight and obesity or with type 2 diabetes.
- Trial name
- NCT06461039
- Testing
- NNC0487-0111 A, NNC0487-0111 C, Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Contraception, Libido
Effects of SH T00658ID on Libido
The aim of the study is to investigate whether women on oral contraceptives (OCs) suffering from acquired OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year will express the same level…
- Trial name
- NCT00764881
- Testing
- EV/DNG (Qlaira, BAY86-5027, SH T00658ID), Microgynon
- Where
- 32 sites in Australia, Austria and 5 more
- Volunteers
- 217 people
- Sponsor
- Bayer
Female Contraception
Bioequivalence Study of Patches With Different Equilibration Profiles
The purpose of this single center, randomized, double-blind, 2 way crossover study was to determine the bioequivalence of a norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.
- Trial name
- NCT00775086
- Testing
- norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception
Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles
Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in approxmiately 1200 women for up to 13 cycles
- Trial name
- NCT05139121
- Testing
- MR-100A-01
- Where
- 100 sites in United States, Canada and 1 more
- Volunteers
- 1,320 people, healthy volunteers welcome
- Sponsor
- Mylan Technologies Inc.
Safety
Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents
To evaluate the safety, compliance, and pharmacokinetics profile of estetrol monohydrate (E4) 15 mg combined with drospirenone (DRSP) 3 mg in post-menarchal participants between the age of 12 and 17 years + 2 months.
- Trial name
- NCT04792385
- Testing
- E4/DRSP 15/3 mg combined tablet
- Where
- 23 sites in Estonia, Finland and 4 more
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Estetra
Female Contraception
Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice
MARILIA is a prospective, non-interventional, multicenter study. The purpose of this study is to describe the acceptability of Amenorrhea in contraception indication of Mirena users during one year follow up in medical practice.
- Trial name
- MARILIA (NCT01833793)
- Testing
- Levonorgestrel IUD (Mirena, BAY86-5028)
- Where
- Algeria
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Retrospective Claims Analysis of Hysterectomy After Sterilization
The research questions are: 1. What is the proportion of women undergoing hysterectomy after hysteroscopic sterilization or laparoscopic tubal ligation? 2.
- Trial name
- NCT02527278
- Testing
- Laparoscopic tubal ligation, Hysteroscopic sterilization
- Where
- United States
- Volunteers
- 19,317 people
- Sponsor
- Bayer
Contraception, Female Contraception
Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.
The purpose of the study is to evaluate user experience with the EVRA® Contraceptive Transdermal Patch; specifically, user satisfaction with the EVRA® Patch, and if applicable, user preference of the EVRA® Patch compared with…
- Trial name
- NCT00261482
- Testing
- norelgestromin + ethinyl estradiol
- Volunteers
- 778 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Contraception
US Ovulation Inhibition Study in Obese Women
Birth Control Patch Study
- Trial name
- NCT00873483
- Testing
- Ethinylestradiol/Gestodene (BAY86-5016)
- Where
- 6 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception, Female Contraception
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with…
- Trial name
- NCT00331071
- Testing
- Monophasic or triphasic Oral contraceptive tablet, Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Female Contraception
Bioequivalence Study of Patches With Different Release Profiles
The purpose of this study was to determine the bioequivalence of a norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.
- Trial name
- NCT00697307
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight, Obesity
A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight
The purpose of this clinical study is to find out if NNC0662-0419 is safe and effective to be taken together with other medicines, like birth control pills, and emptying of the stomach in women not able to become pregnant living…
- Trial name
- NCT07525791
- Testing
- NNC0662-0419, Oral contraceptive, Acetaminophen
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Contraception
Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)
The purpose of this study is to examine and compare the uptake of Yasmin (oral contraceptive containing drospirenone and ethinylestradiol) with or without levomefolate calcium (Metafolin, a registered vitamin supplement) in the…
- Trial name
- NCT01253174
- Testing
- EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131), EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca), L-5-MTHF Ca 0.451 mg (Metafolin)
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraceptive
PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.
Clinical study in which researchers want to learn more about the safety profile of MESIGYNA used as a medication in routine clinical practice to prevent pregnancy.
- Trial name
- PROMES (NCT03901131)
- Testing
- Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)
- Where
- Peru
- Volunteers
- 296 people
- Sponsor
- Bayer
Contraception
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
The Essure System is indicated for women who desire non-incisional permanent birth control (female sterilization) by occlusion of the fallopian tubes.
- Trial name
- NCT01948882
- Testing
- ESS505 (BAY1454033)
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
- Trial name
- NCT05264506
- Testing
- NOMAC-E2 COC
- Where
- 103 sites in United States
- Volunteers
- 3,055 people
- Sponsor
- Organon and Co
Uterine Bleeding Profile Prediction
A Study to Learn More About How a Smartphone App Called MyIUS Predicts Future Menstrual Bleeding in Women After They Have Begun Using Intrauterine Birth Control Method (a Birth Control Device is Inserted Into a Woman's Uterus by Her Doctor)
Researchers are looking to learn more about future menstrual bleeding in women who have started using intrauterine contraception methods.
- Trial name
- MyIUS (NCT04989595)
- Testing
- MyIUS app
- Where
- 6 sites in Brazil, Denmark and 4 more
- Volunteers
- 3,045 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception, Menorrhagia
Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia
The purpose of this study is to assess the bleeding pattern during the last 3 months of the first MIRENA® and the first year of the second MIRENA® use.
- Trial name
- NCT00393198
- Testing
- Levonorgestrel (Mirena, BAY86-5028), Cytotec
- Where
- 17 sites in Finland, France and 2 more
- Volunteers
- 204 people
- Sponsor
- Bayer
Contraception, Female Contraception
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Triphasil.
- Trial name
- NCT00236795
- Testing
- norelgestromin + ethinyl estradiol; triphasil.
- Volunteers
- 1,494 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.